Cowan AJ, Green DJ, Kwok M, et al. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327:464–77.

Article  CAS  PubMed  Google Scholar 

Rollig C, Knop S, Bornhauser M. Multiple myeloma. Lancet. 2015;385:2197–208.

Article  PubMed  Google Scholar 

Kumar SK, Rajkumar V, Kyle RA, et al. Multiple myeloma. Nat Rev Dis Primers. 2017;3:17046.

Article  PubMed  Google Scholar 

Garfall AL. New biological therapies for multiple myeloma. Annu Rev Med. 2024;75:13–29.

Article  CAS  PubMed  Google Scholar 

Kyle RA, Larson DR, Therneau TM, et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. N Engl J Med. 2018;378:241–9.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Mateos MV, Kumar S, Dimopoulos MA, et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 2020;10:102.

Article  PubMed Central  PubMed  Google Scholar 

Landgren O, Weiss BM. Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis. Leukemia. 2009;23:1691–7.

Article  CAS  PubMed  Google Scholar 

Garcia-Ortiz A, Rodriguez-Garcia Y, Encinas J, et al. The role of tumor microenvironment in multiple myeloma development and progression. Cancers. 2021;13:217.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Uckun FM. Overcoming the immunosuppressive tumor microenvironment in multiple myeloma. Cancers. 2021;13:2018.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Hervas-Salcedo R, Martin-Antonio B. A journey through the inter-cellular interactions in the bone marrow in multiple myeloma: implications for the next generation of treatments. Cancers. 2022;14:3796.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Pu J, Liu T, Wang X, et al. Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectives. Exp Hematol Oncol. 2024;13:45.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Mikhael J, Ismaila N, Cheung MC, et al. Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline. J Clin Oncol. 2019;37:1228–63.

Article  PubMed  Google Scholar 

Soekojo CY, Chng WJ. Treatment horizon in multiple myeloma. Eur J Haematol. 2022;109:425–40.

Article  CAS  PubMed  Google Scholar 

Holstein SA, Grant SJ, Wildes TM. Chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma: moving into the future. J Clin Oncol. 2023;41:4416–29.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Tanenbaum B, Miett T, Patel SA. The emerging therapeutic landscape of relapsed/refractory multiple myeloma. Ann Hematol. 2023;102:1–11.

Article  PubMed  Google Scholar 

Cengiz Seval G, Beksac M. A comparative safety review of histone deacetylase inhibitors for the treatment of myeloma. Expert Opin Drug Saf. 2019;18:563–71.

Article  CAS  PubMed  Google Scholar 

Elnair RA, Holstein SA. Evolution of treatment paradigms in newly diagnosed multiple myeloma. Drugs. 2021;81:825–40.

Article  CAS  PubMed  Google Scholar 

Bazarbachi AH, Al Hamed R, Malard F, Bazarbachi A, Harousseau JL, Mohty M. Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update. Blood Cancer J. 2022;12:47.

Article  PubMed Central  PubMed  Google Scholar 

Minnie SA, Hill GR. Immunotherapy of multiple myeloma. J Clin Invest. 2020;130:1565–75.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Joshua DE, Bryant C, Dix C, Gibson J, Ho J. Biology and therapy of multiple myeloma. Med J Aust. 2019;210:375–80.

Article  PubMed  Google Scholar 

Goldschmidt H, Egerer G, Ho AD. Autologous and allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant. 2000;25(Suppl 2):S25-26.

Article  PubMed  Google Scholar 

Gahrton G, Bjorkstrand B. Progress in haematopoietic stem cell transplantation for multiple myeloma. J Intern Med. 2000;248:185–201.

Article  CAS  PubMed  Google Scholar 

Majolino I, Scime R, Indovina A. Autologous blood stem cell transplantation in hematologic malignancies. Haematologica. 1990;75:555–66.

CAS  PubMed  Google Scholar 

Rosenblatt J, Avigan D. Role of immune therapies for myeloma. J Natl Compr Canc Netw. 2015;13:1440–7.

Article  CAS  PubMed  Google Scholar 

Atanackovic D, Radhakrishnan SV, Bhardwaj N, Luetkens T. Chimeric Antigen Receptor (CAR) therapy for multiple myeloma. Br J Haematol. 2016;172:685–98.

Article  PubMed  Google Scholar 

Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20:359–71.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Yu B, Jiang T, Liu D. BCMA-targeted immunotherapy for multiple myeloma. J Hematol Oncol. 2020;13:125.

Article  CAS  PubMed Central  PubMed  Google Scholar 

van de Donk N, Usmani SZ, Yong K. CAR T-cell therapy for multiple myeloma: state of the art and prospects. Lancet Haematol. 2021;8:e446–61.

Article  PubMed  Google Scholar 

Roshandel E, Ghaffari-Nazari H, Mohammadian M, et al. NK cell therapy in relapsed refractory multiple myeloma. Clin Immunol. 2023;246: 109168.

Article  CAS  PubMed  Google Scholar 

Kriegsmann K, Kriegsmann M, Cremer M, et al. Cell-based immunotherapy approaches for multiple myeloma. Br J Cancer. 2019;120:38–44.

Article  PubMed  Google Scholar 

Tomaipitinca L, Russo E, Bernardini G. NK cell surveillance of hematological malignancies. Therapeutic implications and regulation by chemokine receptors. Mol Aspects Med. 2021;80: 100968.

Article  CAS  PubMed  Google Scholar 

San Miguel JF, Paiva B, Lasarte JJ. Engineering Anti-myeloma responses using affinity-enhanced TCR-engineered T cells. Cancer Cell. 2015;28:281–3.

Article  CAS  PubMed  Google Scholar 

Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 2018;8:1219–26.